Ionis Pharmaceuticals IONS Tax Credit Carryforward Valuation Allowance
Tax Credit Carryforward Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's tax credit carryforward valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's tax credit carryforward valuation allowance?
- Ionis Pharmaceuticals (IONS) reported tax credit carryforward valuation allowance of $1.24B in Q4 2025.
- What does tax credit carryforward valuation allowance mean?
- A reserve account indicating the portion of tax credits that might not be usable in the future.
- How do you interpret tax credit carryforward valuation allowance?
- A high or increasing allowance suggests management is uncertain about generating sufficient future taxable income to utilize tax credits.
- How does tax credit carryforward valuation allowance compare across companies?
- Common in biotech/pharma companies that have high R&D credits but inconsistent profitability.